

Aggregate Analysis of Fc-Fusion Proteins

Dr. Ivan Lebedev, Brian Rivera, and Dr. Bryan Tackett
Phenomenex, Inc., 411 Madrid Ave., Torrance, CA 90501 USA

Overview

Fc-fusion proteins are Fc homodimers linked to a polypeptide chain. From an analytical standpoint, Fc-fusion proteins present several challenges. Fc-fusion proteins may have much more complex glycosylation, including deviations from the biantennary fucosylated glycans associated with monoclonal antibodies, as well as O-glycans. As glycosylation directly impacts protein conformation or folding, analytical LC separations may be affected as well. Indeed, even with non-adsorptive separation modalities such as size exclusion chromatography (SEC), separation may require extensive method development for optimization to ensure a robust method.

Figure 2 shows an SEC profile for Etanercept, a heavily glycosylated Fc-TNFR conjugate. Because it often has sialylation, non-ideal SEC interactions can be observed. That is, so-called “ion exclusion” of the protein due to repulsion of the negatively charged protein and inherently negative silica. This can cause peak broadening and/or adsorption of the protein, which can prevent the proper quantitation of the protein. As such, the mobile phase used should have sufficient co-solvent (i.e. NaCl or other salt) to minimize this effect. Using a 2X Phosphate Buffered Saline as the mobile phase ensures that any electrostatic interaction is minimized. Thus, percent monomer and aggregate can be easily calculated, using standard integration parameters, with percent monomer being 96.9% by peak area.

This strategy can be implemented for other Fc-Fusion proteins which potentially can present similar issues.

Figure 3 shows a SEC profile for Aflibercept, an Fc-Fusion protein conjugated to VEGF receptor. Although not as complex as Etanercept, Aflibercept being a Fc-Fusion protein often has physicochemical properties that are not as predictable as a canonical IgG1 monoclonal antibody.

LC Conditions

Column: Biozen™ 3 µm dSEC-2, 200 Å
Dimension: 300 x 7.8 mm
Part No.: [00H-4788-K0](#)
Mobile Phase: 50 mM Sodium Phosphate + 300 mM NaCl, pH 6.8
Flow Rate: 1.15 mL/min
Injection Volume: 10 µL
Temperature: 30 °C
Detection: UV @ 280 nm
Sample: As indicated




Figure 1. Structure of Etanercept



Figure 2. SEC Profile for Etanercept (25 mg/mL)

SEC Chromatogram for Etanercept, showing good separation of monomer and aggregate. Monomer purity is 96.9% by peak area.





Figure 3. SEC Profile for Aflibercept (25 mg/mL)

SEC Chromatogram for Aflibercept, showing good separation of monomer and aggregate. Monomer purity is 96.8% by peak area.



Need a different column size or sample preparation format?

No problem! We have a majority of our available dimensions up on www.phenomenex.com, but if you can't find what you need right away, our super helpful Technical Specialists can guide you to the solution via our online chat portal www.phenomenex.com/LiveChat.

Australia

t: +61 (0)2-9428-6444
auiinfo@phenomenex.com

Austria

t: +43 (0)1-319-1301
anfrage@phenomenex.com

Belgium

t: +32 (0)2 503 4015 (French)
t: +32 (0)2 511 8666 (Dutch)
beinfo@phenomenex.com

Canada

t: +1 (800) 543-3681
info@phenomenex.com

China

t: +86 400-606-8099
cninfo@phenomenex.com

Czech Republic

t: +420 272 017 077
cz-info@phenomenex.com

Denmark

t: +45 4824 8048
nordicinfo@phenomenex.com

Finland

t: +358 (0)9 4789 0063
nordicinfo@phenomenex.com

France

t: +33 (0)1 30 09 21 10
franceinfo@phenomenex.com

Germany

t: +49 (0)6021-58830-0
anfrage@phenomenex.com

Hong Kong

t: +852 6012 8162
hkinfo@phenomenex.com

India

t: +91 (0)40-3012 2400
indiainfo@phenomenex.com

Indonesia

t: +62 21 5010 9707
indoinfo@phenomenex.com

Ireland

t: +353 (0)1 247 5405
eireinfo@phenomenex.com

Italy

t: +39 051 6327511
italiainfo@phenomenex.com

Japan

t: +81 (0) 120-149-262
jpinfo@phenomenex.com

Luxembourg

t: +31 (0)30-2418700
nlinfo@phenomenex.com

Mexico

t: 01-800-844-5226
tecnicomx@phenomenex.com

The Netherlands

t: +31 (0)30-2418700
nlinfo@phenomenex.com

New Zealand

t: +64 (0)9-4780951
nzinfo@phenomenex.com

Norway

t: +47 810 02 005
nordicinfo@phenomenex.com

Poland

t: +48 22 104 21 72
pl-info@phenomenex.com

Portugal

t: +351 221 450 488
ptinfo@phenomenex.com

Singapore

t: +65 800-852-3944
sginfo@phenomenex.com

Slovakia

t: +420 272 017 077
sk-info@phenomenex.com

Spain

t: +34 91-413-8613
espinfo@phenomenex.com

Sweden

t: +46 (0)8 611 6950
nordicinfo@phenomenex.com

Switzerland

t: +41 (0)61 692 20 20
swissinfo@phenomenex.com

Taiwan

t: +886 (0) 0801-49-1246
twinfo@phenomenex.com

Thailand

t: +66 (0) 2 566 0287
thaiinfo@phenomenex.com

United Kingdom

t: +44 (0)1625-501367
ukinfo@phenomenex.com

USA

t: +1 (310) 212-0555
info@phenomenex.com

🌐 **All other countries/regions**
Corporate Office USA
t: +1 (310) 212-0555
info@phenomenex.com

www.phenomenex.com

Phenomenex products are available worldwide. For the distributor in your country/region, contact Phenomenex USA, International Department at international@phenomenex.com

BE-HAPPY™
GUARANTEE

Your happiness is our mission. Take 45 days to try our products. If you are not happy, we'll make it right.

www.phenomenex.com/behappy

Terms and Conditions

Subject to Phenomenex Standard Terms and Conditions, which may be viewed at www.phenomenex.com/TermsAndConditions.

Trademarks

Biozen and BE-HAPPY are trademarks of Phenomenex.

FOR RESEARCH USE ONLY. Not for use in clinical diagnostic procedures.

© 2021 Phenomenex, Inc. All rights reserved.

